focus -WSS

focus

author：entertainment 2025-09-29 01:09:19 - browse：481

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

WSS

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

2024 GOP presidential candidates spar over abortion in debate

How a symptom of dementia informs our understanding of creativity

Neuroscience startup Neumora files for IPO

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

focus

hotspot

Psychedelics group wrestles with new pharma identity

Neuroscience startup Neumora files for IPO

Continuity nursing helped my family in our darkest PICU moments

STAT Readout Newsletter: Biotech news today

After affirmative action ruling, medical educators look to 'holistic review'

Study on Amgen’s bispecific immunotherapy produces positive data

As demand for Covid shots wanes, Moderna seeks its next success

Radiation, mainstay of cancer treatment, begins a fade

Psychedelics group wrestles with new pharma identity

NYU Langone launches private ChatGPT for its health care data

Wikipedia

STAT Summit: Ending the crisis of Black deaths in the U.S.

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

J&J lung cancer data amount to new salvo against AstraZeneca

How to make AI work for medicine

How to make Best Hospitals ratings actually useful for patients

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

explore

leisure time

leisure time

leisure time